Evergreen Theragnostics is a US-based leader in radiopharmaceutical manufacturing and development, specialising in theragnostic solutions for precision medicine.
Founded in 2019 and headquartered in Springfield, New Jersey, Evergreen Theragnostics operates as a Contract Development and Manufacturing Organisation (CDMO) dedicated to supporting the full lifecycle of radiopharmaceuticals. The company leverages its state-of-the-art GMP-certified facility to offer robust manufacturing services for therapeutic and diagnostic products, with a strong focus on oncology and precision medicine. Evergreen combines innovation with reliability, enabling seamless development, production, and commercialisation of advanced radiopharmaceuticals.
Key Products and Services:
- CDMO Services: Comprehensive support for radiopharmaceutical development, manufacturing, and regulatory compliance.
- Therapeutic Radiopharmaceuticals: Expertise in producing targeted alpha therapy (TAT) agents using isotopes like Actinium-225 and Thorium-227.
- Diagnostic Radiopharmaceuticals: Development and production of imaging agents, including the Gallium-68 DOTATOC kit for neuroendocrine tumour diagnostics.
- Customised Solutions: Facility design and manufacturing capabilities tailored to unique client requirements.
Evergreen Theragnostics is committed to advancing patient-centric therapies in the rapidly growing radiopharmaceutical market. By combining cutting-edge technology with extensive industry expertise, the company remains at the forefront of innovation, ensuring effective and reliable solutions that meet the evolving demands of precision medicine.
